# ATR Kinase: Replication Stress Response, ATRIP Complexing, and Synthetic Lethality in Cancer


## Key Takeaways

- ATR (Ataxia Telangiectasia and Rad3-related) is a serine/threonine-protein kinase and the master regulator of the cellular replication stress response, essential for genome integrity and viability in metazoans. It functions by sensing single-stranded DNA (ssDNA) lesions and activating downstream effectors that orchestrate cell cycle arrest, DNA repair, replication fork stabilization, and apoptosis.
- ATR forms a constitutive heterodimer with ATRIP, which acts as the sensor module by binding to RPA-coated ssDNA at stalled replication forks or resected double-strand breaks, thereby recruiting the ATR-ATRIP complex to sites of damage for activation.
- ATR activation is further modulated by protein complexes like RAD9-RAD1-HUS1 (9-1-1) loaded by RAD17-RFC, which recruits TOPBP1, or by ETAA1, leading to allosteric activation of ATR's kinase domain. Activated ATR then phosphorylates key effectors such as CHK1, BRCA1, and WEE1, propagating the DNA damage response and enforcing cell cycle checkpoints.
- The therapeutic rationale for ATR inhibition in cancer is based on synthetic lethality, where tumors with deficiencies in parallel DNA repair pathways (e.g., ATM loss) or those experiencing high replication stress become exquisitely sensitive to ATR inhibitors, leading to catastrophic genome instability and cell death.
- Germline hypomorphic mutations in *ATR* cause Seckel syndrome type 1, characterized by severe growth retardation and microcephaly, while somatic *ATR* mutations are observed in various cancers, often in conjunction with other DNA damage response defects, contributing to tumorigenesis and aggressive disease.
- Several selective ATR inhibitors, including Ceralasertib, Berzosertib, Elimusertib, and Camonsertib, are in clinical development for a range of solid tumors and hematologic malignancies, often in combination strategies with chemotherapy, radiotherapy, or other targeted agents, with anemia being a notable dose-limiting toxicity.

---

## Executive Summary & Key Metadata

The **ATR** (Ataxia Telangiectasia and Rad3-related) gene encodes a 2,644-amino-acid serine/threonine-protein kinase that functions as the master regulator of the cellular replication stress response. As a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family, ATR orchestrates the DNA damage response (DDR) by sensing single-stranded DNA (ssDNA) lesions and activating downstream effectors that coordinate cell cycle arrest, DNA repair, replication fork stabilization, and apoptosis [1, 2]. ATR is essential for viability in metazoans; complete knockout results in early embryonic lethality in mice, underscoring its non-redundant role in maintaining genome integrity during development [3]. In cancer biology, ATR has emerged as a high-value therapeutic target due to the concept of synthetic lethality: tumors harboring deficiencies in parallel DNA repair pathways—particularly those with ATM loss or replication stress overload—are exquisitely sensitive to ATR inhibition [4, 5, 6].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ATR |
| UniProt Accession | Q13535 |
| Representative PDB ID | 5ZF0 |
| Chromosomal Locus | 3q23 (GRCh38: chr3:142,449,235-142,578,778) |
| Primary Molecular Function | Serine/threonine kinase; DNA damage checkpoint signaling; replication stress response |
| Disease & Pathology Associations | Seckel syndrome (ATR hypomorphism); cutaneous telangiectasia; cancer susceptibility (breast, ovarian, colorectal, lymphoid malignancies); ATR inhibitor sensitivity in ATM-deficient tumors |
| Key Interactors | ATRIP, TOPBP1, ETAA1, CLSPN (Claspin), CHK1, RAD17, RPA, [BRCA1](/knowledge/bioinformatics/genes/cancer-genomics/brca1-gene-mutation-dna-repair), WEE1 |
| Inhibitors (Clinical/Investigational) | Ceralasertib (AZD6738), Elimusertib (BAY1895344), Camonsertib (RP-3500), Berzosertib (VE-822) |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *ATR* gene is located on the long arm of chromosome 3 at cytogenetic band **3q23**. The gene spans approximately 129.5 kilobases of genomic DNA on the plus strand, encompassing 47 exons that produce a mature mRNA of approximately 8.5 kb. The coding sequence (CDS) is 7,935 nucleotides in length, encoding the full-length 2,644-amino-acid protein. The genomic coordinates per GRCh38/hg38 assembly are chr3:142,449,235–142,578,778.

The promoter region of *ATR* lacks a canonical TATA box but contains multiple GC-rich elements and CpG islands, characteristic of constitutively expressed housekeeping genes. However, *ATR* expression is not entirely static; it is modestly upregulated in response to genotoxic stress and during S-phase entry. Transcription factor binding site analysis reveals consensus motifs for E2F family members, SP1, and NF-κB within the proximal promoter. The NF-κB regulatory axis is particularly notable: the NF-κB-regulated gene *CLSPN* (encoding Claspin), an essential ATR activator, is co-regulated with ATR under conditions of inflammatory stress, suggesting a coordinated transcriptional program for checkpoint signaling [7, 8].

### 1.2 Alternative Splicing and Isoforms

Alternative splicing of *ATR* mRNA produces several transcript variants, although the functional significance of most remains incompletely characterized. The canonical transcript (ENST00000354687.9) encodes the full-length kinase. A well-documented splice variant involves exon 12 skipping, which introduces a frameshift and premature termination codon, yielding a truncated protein lacking the kinase domain [9]. This variant is subject to nonsense-mediated decay (NMD), suggesting it represents a regulatory mechanism rather than a functional isoform. Additional minor variants have been identified in testis and fetal tissues, but their protein products have not been biochemically validated [9].

The 5' untranslated region (UTR) of *ATR* mRNA is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that repress translation under normal conditions. This structural feature permits rapid translational upregulation in response to replication stress, as the uORF-mediated repression is relieved upon phosphorylation of eIF2α by GCN2 or PERK. This mechanism ensures that ATR protein levels can be quickly elevated when cells encounter genotoxic challenges, complementing the post-translational activation of pre-existing ATR pools.

### 1.3 Regulatory Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal that the *ATR* locus is decorated with H3K4me3 marks at the promoter and H3K27ac at distal enhancer elements located approximately 15 kb upstream and 30 kb downstream of the transcription start site. These enhancers are bound by CTCF and cohesin, suggesting that the *ATR* locus participates in topologically associating domain (TAD) boundaries that facilitate long-range interactions with other DDR genes. Single-nucleotide polymorphisms (SNPs) within these enhancer regions have been associated with altered ATR expression levels in population studies, though the phenotypic consequences remain subtle.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Architecture of the ATR Polypeptide

The ATR protein is a large (301.6 kDa) polypeptide that adopts a modular architecture characteristic of the PIKK family. The protein can be divided into five major structural regions: (1) the N-terminal HEAT-repeat domain, (2) the α-helical FAT domain, (3) the kinase domain (KD), (4) the PIKK-regulatory domain (PRD), and (5) the C-terminal FATC domain. The HEAT repeats (named for Huntingtin, EF3, PP2A, and TOR1) comprise approximately 40 tandem α-helical hairpin motifs that mediate protein-protein interactions, particularly with ATRIP. The FAT domain (named for FRAP, ATM, and TRRAP) and FATC domain flank the kinase domain and are required for proper folding and catalytic activity [1].

### 2.2 The Kinase Domain and Catalytic Mechanism

The kinase domain of ATR (residues approximately 2327–2644) adopts the canonical bilobed protein kinase fold, with an N-terminal lobe rich in β-sheets and a C-terminal lobe dominated by α-helices. The catalytic loop contains the conserved DFG motif (Asp-Glu-Phe) and the HRD motif (His-Arg-Asp) essential for phosphotransfer. ATR phosphorylates substrates on serine or threonine residues followed by glutamine (the SQ/TQ motif), a specificity shared with ATM and DNA-PKcs. The ATP-binding pocket is located at the interface of the two lobes and is the target of all clinically relevant ATR inhibitors [1, 2].

A distinguishing feature of the ATR kinase domain is the presence of an insertion loop between the N- and C-lobes that is longer than that found in conventional kinases. This "PIKK insertion" creates a deep hydrophobic groove that accommodates the bulky purine-based inhibitors such as berzosertib and ceralasertib, conferring selectivity over the closely related [ATM kinase](/knowledge/bioinformatics/genes/cancer-genomics/atm-gene-structure-function-pathway) [1].

### 2.3 The ATR-ATRIP Complex

ATR exists as a stable heterodimer with ATRIP (ATR-Interacting Protein) in a 1:1 stoichiometry. The interaction is mediated by the N-terminal HEAT repeats of ATR (residues 1–400) and the C-terminal coiled-coil domain of ATRIP. This association is constitutive and does not require DNA damage; however, the complex undergoes conformational rearrangements upon binding to RPA-coated ssDNA. ATRIP functions as the sensor module: it directly binds to the 70-kDa subunit of replication protein A (RPA70) that coats ssDNA at stalled replication forks or resected double-strand breaks. This RPA-ATRIP interaction recruits the ATR-ATRIP complex to sites of damage, positioning ATR in proximity to its activators and substrates [3].

The importance of ATRIP is underscored by the phenotype of ATRIP-deficient patients, who present with microcephalic primordial dwarfism, compromised immunity, and cellular hallmarks of replication stress—a phenotype overlapping with Seckel syndrome caused by ATR hypomorphism [3].

### 2.4 Structural Basis of ATR Activation

Activation of ATR requires the recruitment of additional factors. The heterotrimeric RAD9-RAD1-HUS1 (9-1-1) clamp is loaded onto DNA at junctions of ssDNA and double-stranded DNA (dsDNA) by the RAD17-RFC2-5 clamp loader. The 9-1-1 clamp then recruits TOPBP1 (Topoisomerase II Binding Protein 1) via a phospho-dependent interaction. TOPBP1 contains multiple BRCT domains; the BRCT domains 5–8 interact with the ATR-ATRIP complex and stimulate ATR kinase activity through a direct allosteric mechanism. Specifically, the ATR-activation domain (AAD) of TOPBP1 binds to a surface on the ATR kinase domain, inducing a conformational change that aligns the catalytic residues for optimal phosphotransfer [4].

A second, TOPBP1-independent activation pathway involves the protein ETAA1 (Ewing Tumor Associated Antigen 1). ETAA1 contains an RPA-binding motif and an AAD that directly activates ATR without requiring the 9-1-1 clamp or TOPBP1. Quantitative phosphoproteomics has revealed that ETAA1 and TOPBP1 activate ATR toward partially overlapping but distinct substrate pools, with ETAA1 playing a particularly important role during normal S-phase progression and mitosis [5].

### 2.5 Representative Structure (PDB: 5ZF0)

The representative structure 5ZF0 corresponds to the kinase domain of human ATR in complex with a selective inhibitor. This structure reveals the ATP-binding pocket in its "DFG-in" active conformation, with the inhibitor occupying the adenine-binding region and extending into the hydrophobic PIKK-insertion pocket. The structure has been instrumental in [structure-based drug design](/knowledge/bioinformatics/structure-based-drug-design-bioinformatics) efforts, enabling the optimization of selectivity and pharmacokinetic properties of ATR inhibitors [1, 2].

> **[Interactive 3D Protein Visualizer: Load ATR (PDB: 5ZF0)](/tools/protein-structure-viewer?source=direct&pdbId=5ZF0)**

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Replication Stress Response

The primary function of ATR is to coordinate the cellular response to replication stress—a condition characterized by stalled or slowed replication fork progression. Replication stress arises from various sources, including nucleotide depletion, DNA lesions that block polymerase progression, secondary structures such as G-quadruplexes and R-loops, and collisions between the replication machinery and transcription complexes [6, 7].

When a replication fork stalls, the replicative helicase (CMG complex) continues to unwind DNA ahead of the blocked polymerase, generating a stretch of ssDNA. This ssDNA is rapidly coated by RPA, creating a high-affinity binding platform for ATRIP. The recruitment of ATR-ATRIP to RPA-ssDNA is the initiating event in the replication stress response. Subsequently, the 9-1-1 clamp and TOPBP1 are recruited, leading to full ATR activation [4, 8].

### 3.2 Downstream Phosphorylation Cascades

Once activated, ATR phosphorylates a broad spectrum of substrates, with the checkpoint kinase CHK1 being the most critical effector. ATR phosphorylates CHK1 on Ser317 and Ser345, which are located in the SQ/TQ cluster domain of CHK1. This phosphorylation is facilitated by the adaptor protein Claspin, which binds both ATR and CHK1, positioning CHK1 for efficient phosphorylation [7, 9]. Phosphorylated CHK1 then dissociates from chromatin and propagates the checkpoint signal throughout the cell.

CHK1 phosphorylates and inhibits CDC25A, CDC25B, and CDC25C phosphatases, preventing the dephosphorylation and activation of CDK1 and CDK2. This results in cell cycle arrest at the G1/S and G2/M boundaries, providing time for DNA repair. CHK1 also phosphorylates WEE1, a kinase that inhibits CDK1 by phosphorylation of Tyr15, further enforcing the checkpoint [1, 2].

Beyond CHK1, ATR directly phosphorylates numerous other substrates involved in DNA repair and replication fork stabilization:

- **BRCA1**: ATR phosphorylates BRCA1 at multiple SQ/TQ sites (Ser1423, Ser1457, Ser1524), promoting its recruitment to sites of damage and its role in homologous recombination repair [3, 4].
- **RAD17**: Phosphorylation of RAD17 at Ser635 and Ser645 is required for the loading of the 9-1-1 clamp [4].
- **SMARCAL1 and ZRANB3**: These DNA translocases are phosphorylated by ATR to promote replication fork remodeling and regression, protecting stalled forks from nucleolytic degradation.
- **FANCD2 and FANCI**: ATR phosphorylates these Fanconi anemia proteins, promoting their monoubiquitination and activation of the Fanconi anemia DNA repair pathway [5].
- **p53**: ATR can directly phosphorylate p53 at Ser15, contributing to p53 stabilization and transcriptional activation of pro-apoptotic and cell cycle arrest genes [6].
- **CtIP**: Phosphorylation of CtIP at T855 by ATR promotes DNA end resection and homologous recombination [7].

### 3.3 The S/G2 Checkpoint

Recent work has identified a novel, intrinsic S/G2 checkpoint enforced by ATR that is distinct from the classical G2/M checkpoint [7, 8]. This checkpoint operates during normal, unperturbed S-phase and restrains the premature activation of CDK1-dependent phosphorylation of FOXM1, a transcription factor that drives expression of G2/M genes. By preventing premature S-phase shutdown, this ATR-enforced checkpoint ensures that DNA replication is completed before mitotic entry. Loss of this checkpoint leads to genome instability, including micronuclei formation and chromosome segregation errors [7, 8].

### 3.4 ATR in Transcription-Associated Stress

ATR also plays a critical role in managing transcription-associated replication stress. During epithelial-to-mesenchymal transition (EMT), cancer cells undergo massive transcriptional reprogramming that generates R-loops (RNA-DNA hybrids) and conflicts between transcription and replication machineries. ATR is required to resolve these conflicts and enable the transcription reprogramming necessary for EMT [6]. Cells with reduced ATR activity fail to undergo EMT efficiently, suggesting that ATR safeguards the plasticity required for metastasis [6].

### 3.5 Protein-Protein Interaction Network

The ATR interaction network is extensive. BioGRID lists over 200 physical interactors, while STRING analysis reveals a densely connected hub centered on ATR. Key nodes in this network include:

- **ATRIP**: Constitutive binding partner and sensor module.
- **TOPBP1**: Allosteric activator.
- **ETAA1**: Alternative activator.
- **CLSPN (Claspin)**: Adaptor for CHK1 phosphorylation.
- **RPA70/32/14**: ssDNA sensor complex.
- **RAD17/RFC2-5**: Clamp loader.
- **RAD9-RAD1-HUS1**: 9-1-1 clamp.
- **CHK1**: Primary effector kinase.
- **BRCA1**: Tumor suppressor and repair factor.
- **WEE1**: CDK inhibitory kinase.
- **Tel2-Tti1-Tti2 (TTT) complex**: Chaperone complex required for ATR stability and assembly [9].

The TTT complex is particularly important: it associates with the HSP90 chaperone system to facilitate proper folding and assembly of all PIKK family members. Mutations that destabilize the TTT complex lead to reduced ATR protein levels and impaired checkpoint signaling [9].

### 3.6 ATR in Meiosis and Development

Beyond its roles in somatic cells, ATR is essential for meiosis. During prophase I, ATR localizes to unsynapsed chromosomes and mediates the meiotic checkpoint that monitors synapsis [1, 2]. ATR phosphorylates HORMAD2, a meiosis-specific protein, which is required for the surveillance of synapsis and the elimination of defective oocytes [1]. In mammalian follicle development, ATR function is indispensable for proper oocyte maturation [3].

```mermaid
sequenceDiagram
    participant SSB as "Stalled Replication Fork"
    participant RPA as "RPA-ssDNA"
    participant ATRIP as "ATRIP"
    participant ATR as "ATR"
    participant 911 as "9-1-1 Clamp"
    participant TOPBP1 as "TOPBP1"
    participant CHK1 as "CHK1"
    participant CDC25 as "CDC25 Phosphatase"
    participant CDK as "CDK1/CDK2"
    participant WEE1 as "WEE1 Kinase"
    SSB->>RPA: Exposed ssDNA coated by RPA
    RPA->>ATRIP: RPA70 binds ATRIP
    ATRIP->>ATR: Recruits ATR-ATRIP complex
    SSB->>911: RAD17 loads 9-1-1 clamp
    911->>TOPBP1: Recruits TOPBP1
    TOPBP1->>ATR: Allosteric activation via AAD
    ATR->>CHK1: Phosphorylates Ser317/Ser345
    CHK1->>CDC25: Phosphorylates and inhibits
    CDC25-->>CDK: Loss of activating dephosphorylation
    CHK1->>WEE1: Phosphorylates and activates
    WEE1->>CDK: Inhibitory phosphorylation (Tyr15)
    CDK-->>Cell Cycle: G1/S and G2/M arrest
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Seckel Syndrome

Biallelic hypomorphic mutations in *ATR* cause **Seckel syndrome type 1** (MIM #210600), an autosomal recessive disorder characterized by severe intrauterine growth retardation, microcephaly, bird-headed facial appearance, and mild-to-moderate intellectual disability. The most well-characterized mutation is a splice-site variant (c.6764-2A>G) that leads to reduced levels of correctly spliced ATR mRNA, resulting in approximately 5–10% of normal ATR protein levels. This residual activity is sufficient to support embryonic development but insufficient for normal growth and neurogenesis [4].

More recently, ATRIP deficiency has been identified as a phenotypically similar condition, with patients presenting with microcephalic primordial dwarfism, combined immunodeficiency, and cellular hallmarks of replication stress [3]. This phenotypic overlap confirms the functional interdependence of ATR and ATRIP.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *ATR* are observed across multiple cancer types, though they are rarely homozygous loss-of-function events. The Cancer Genome Atlas (TCGA) data reveal that *ATR* mutations occur in approximately 2–5% of tumors, with enrichment in certain subtypes:

- **Breast and Ovarian Cancer**: Germline variants in *ATR* have been investigated as potential low-penetrance susceptibility alleles. Heikkinen et al. (2005) screened familial breast and ovarian cancer families and identified several missense variants, though none showed clear segregation with disease [5]. However, the presence of *ATR* mutations in combination with other DDR defects may contribute to cancer risk.
- **Lymphoid Malignancies**: Pyothorax-associated lymphoma (PAL), a B-cell lymphoma associated with chronic inflammation, shows a high frequency of *ATR* alterations, including mutations and loss of heterozygosity [6]. These alterations likely contribute to the genomic instability characteristic of these tumors.
- **Colorectal Cancer**: *ATR* functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. Mice with reduced ATR expression develop tumors earlier and with higher frequency when combined with MMR deficiency, suggesting that ATR haploinsufficiency can promote tumorigenesis [7].
- **Renal Cell Carcinoma**: Concurrent *ATR* and *BRCA2* mutations have been reported in a case of clear cell renal cell carcinoma with sarcomatoid differentiation and extensive metastases, suggesting that combined DDR defects may drive aggressive disease [8].

### 4.3 Functional Consequences of ATR Mutations

Missense mutations in the kinase domain of ATR can have dominant-negative effects. Expression of kinase-dead ATR mutants (e.g., D2475A) in cells with wild-type ATR increases sensitivity to UV and ionizing radiation and abrogates cell cycle checkpoint control [9]. This dominant-negative behavior has important implications for tumor biology: even heterozygous mutations that produce a defective kinase domain can impair ATR signaling.

### 4.4 ATR Haploinsufficiency and Clinical Phenotypes

O'Driscoll et al. (2007) described patients with heterozygous *ATR* mutations who present with a milder phenotype than Seckel syndrome, including microcephaly, mild growth retardation, and cellular radiosensitivity [4]. This haploinsufficiency phenotype highlights the gene dosage sensitivity of ATR and has implications for cancer susceptibility in carriers of ATR mutations.

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Manipulation of ATR Signaling

Several viruses have evolved mechanisms to manipulate ATR signaling, either to promote or suppress the replication stress response depending on their replication strategy.

**Simian Virus 40 (SV40)**: The SV40 Large T antigen (LT) induces expression of interferon-stimulated genes (ISGs) through an ATR-dependent mechanism [1, 2]. This is unexpected, as ISG induction is typically associated with innate immune signaling. The finding suggests that ATR activation by LT creates a signaling environment that mimics viral infection, potentially contributing to the antiviral state. Mechanistically, LT expression leads to replication stress, which activates ATR, which in turn phosphorylates and activates IRF3 or other transcription factors involved in ISG expression [1].

**Herpes Simplex Virus 1 (HSV-1)**: HSV-1 activates the ATR pathway during infection, and this activation is required for efficient viral replication [3]. The virus likely exploits ATR signaling to maintain a replication-competent environment in the host nucleus. Inhibition of ATR reduces HSV-1 replication, suggesting that ATR inhibitors could have antiviral activity.

**Adeno-Associated Virus (AAV)**: Recombinant AAV transduction induces a DNA damage response characterized by ATR activation [4]. This response may influence the efficiency of AAV-mediated gene delivery, as DDR activation can affect viral genome integration and expression.

### 5.2 Parasitic Pathogens

**Trypanosoma brucei**: The ATR kinase in *T. brucei* links DNA damage signaling to the monoallelic control of variant surface glycoprotein (VSG) expression during antigenic variation [5]. This parasite uses ATR to coordinate the switching of VSG genes, a process that involves DNA recombination events. ATR inhibition in *T. brucei* disrupts VSG switching, potentially providing a therapeutic target for African sleeping sickness [5].

### 5.3 Bacterial Effectors and Immune Evasion

While direct bacterial manipulation of ATR is less well-characterized than viral manipulation, certain bacterial genotoxins (e.g., cytolethal distending toxin from *Campylobacter jejuni* and *Helicobacter pylori*) induce DNA damage that activates ATR signaling. This activation can lead to cell cycle arrest and apoptosis, which may contribute to the pathology of bacterial infections.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 ATR as a Therapeutic Target

The rationale for targeting ATR in cancer therapy stems from the concept of synthetic lethality. Tumors with defects in the ATM-p53 pathway or with high levels of replication stress are particularly dependent on ATR for survival. Inhibition of ATR in these contexts leads to catastrophic genome instability and cell death [2, 4, 6].

### 6.2 Clinical-Stage ATR Inhibitors

Several selective ATR inhibitors have entered clinical development:

| **Drug** | **Alternative Names** | **Developer** | **Phase** | **Key Indications** |
|---|---|---|---|---|
| **Ceralasertib** | AZD6738 | AstraZeneca | Phase II/III | ATM-deficient tumors, NSCLC, melanoma, MDS/CMML [6] |
| **Berzosertib** | VE-822, M6620 | Merck KGaA | Phase II | Ovarian cancer, SCLC, combination with chemotherapy |
| **Elimusertib** | BAY1895344 | Bayer | Phase I/II | ATRX-mutated uterine leiomyosarcoma, solid tumors [7] |
| **Camonsertib** | RP-3500 | Repare Therapeutics | Phase I/II | Biomarker-selected solid tumors with DDR deficiencies [8] |
| **M4344** | VX-803 | Vertex | Phase I | Advanced solid tumors |

### 6.3 Camonsertib (RP-3500) and the TRESR Study

The TRESR study evaluated camonsertib in patients with biomarker-selected advanced solid tumors, focusing on tumors with alterations in *ATM*, *ATR*, *CHEK2*, or other DDR genes [8]. The study identified on-target anemia as the main dose-limiting toxicity, typically manifesting after the dose-limiting toxicity period. Dose optimization strategies, including intermittent dosing schedules, have been implemented to mitigate hematologic toxicity while maintaining antitumor efficacy [8].

### 6.4 Elimusertib in ATRX-Mutated Leiomyosarcoma

Uterine leiomyosarcoma (uLMS) frequently harbors alterations in the *ATRX* gene, which encodes a chromatin remodeler involved in alternative lengthening of telomeres (ALT). Preclinical studies demonstrated that ATRX-mutated uLMS models are sensitive to elimusertib, and this agent is being evaluated clinically in this patient population [7].

### 6.5 ATR Inhibitors in Hematologic Malignancies

**Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)**: Mutations in splicing factor genes such as *SRSF2* create a dependency on ATR/CHK1/WEE1 signaling [9]. Ceralasertib has shown preliminary activity in this patient population, particularly in those with spliceosome mutations [6].

**MLL-Rearranged AML**: Preclinical studies demonstrated that targeting both ATR and ATM exhibits therapeutic potential in a mouse model of MLL-rearranged AML [1]. The combination of ATR and ATM inhibitors may be particularly effective in this aggressive leukemia subtype.

**Diffuse Large B-Cell Lymphoma (DLBCL)**: Dark zone-like DLBCL (DZ-DLBCL) shows resistance to conventional chemotherapy. ATR inhibition combined with nucleoside analog therapy synergistically overcomes chemoresistance and reprograms DZ-DLBCL toward immune-accessible phenotypes [2].

**Chronic Lymphocytic Leukemia (CLL)**: CLL with DNA damage response defects, particularly those with ATM loss or p53 dysfunction, shows synthetic lethality when treated with ATR inhibitors [6].

### 6.6 ATR Inhibitors in Solid Tumors

**Prostate Cancer**: ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer models [5]. This finding has significant clinical implications, as PARP inhibitors are currently the standard of care for DDR-deficient prostate cancer, but ATR inhibitors may be more effective in ATM-deficient tumors.

**Neuroblastoma**: DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition [3]. The combination of PARP and ATR inhibitors may be particularly effective in pediatric solid tumors with DDR defects.

**Non-Small Cell Lung Cancer (NSCLC)**: LKB1 deficiency and KEAP1/NRF2 pathway alterations have been proposed as biomarkers of response to ATR and ATM inhibitors in NSCLC [4]. These alterations are common in KRAS-mutant NSCLC and are associated with poor prognosis.

**Colorectal Cancer**: The ruthenium drug BOLD-100 regulates BRAF-mutant colorectal cancer cell apoptosis through the AhR/ROS/ATR signaling axis [5]. This suggests that ATR modulation may be relevant in BRAF-mutant CRC, which is resistant to standard therapies.

### 6.7 Combination Strategies

ATR inhibitors are being evaluated in combination with:

- **PARP inhibitors**: Synthetic lethality enhancement in BRCA-deficient tumors [3, 4].
- **Chemotherapy**: Nucleoside analogs, platinum agents, topoisomerase inhibitors [2, 6].
- **Radiotherapy**: ATR inhibition radiosensitizes tumors by preventing checkpoint activation [7].
- **Immunotherapy**: ATR inhibition may enhance antitumor immunity by increasing neoantigen burden and PD-L1 expression [8].
- **WEE1 inhibitors**: Dual blockade of the ATR-CHK1-WEE1 axis [1, 9].
- **ATM inhibitors**: Dual targeting of parallel DDR pathways [1, 4].

### 6.8 Resistance Mechanisms

Resistance to ATR inhibitors can arise through multiple mechanisms:

- **Loss of Cyclin C or CDK8**: Suppresses transcription-associated replication stress, reducing ATR dependency [9].
- **RB1 loss**: Retinoblastoma status predicts ATR inhibitor sensitivity, with RB1-deficient tumors showing reduced sensitivity [1].
- **Upregulation of RRM2**: Increased ribonucleotide reductase activity reduces replication stress, decreasing ATR dependency [2].
- **Activation of compensatory pathways**: Upregulation of ATM or DNA-PKcs can partially compensate for ATR loss [4].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 545 | https://www.ncbi.nlm.nih.gov/gene/545 |
| Ensembl | ENSG00000175054 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175054 |
| UniProt | Q13535 | https://www.uniprot.org/uniprotkb/Q13535 |
| RCSB PDB | 5ZF0 | https://www.rcsb.org/structure/5ZF0 |
| HGNC | 882 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:882 |
| OMIM | 601215 | https://www.omim.org/entry/601215 |
| ClinVar | ATR | https://www.ncbi.nlm.nih.gov/clinvar/?term=ATR%5Bgene%5D |
| COSMIC | ATR | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATR |
| Gene Ontology (Biological Process) | GO:0006974 (DNA damage response), GO:0030330 (DNA damage response, signal transduction by p53 class mediator), GO:0006281 (DNA repair) | https://www.ebi.ac.uk/QuickGO/ |
| Gene Ontology (Molecular Function) | GO:0004674 (protein serine/threonine kinase activity), GO:0005524 (ATP binding), GO:0019901 (protein kinase binding) | https://www.ebi.ac.uk/QuickGO/ |
| Gene Ontology (Cellular Component) | GO:0005634 (nucleus), GO:0005654 (nucleoplasm), GO:0035861 (site of double-strand break) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | 9606.ENSP00000354687 | https://string-db.org/ |
| BioGRID | 106638 | https://thebiogrid.org/106638 |
| Reactome | R-HSA-5693532 (ATR signaling) | https://reactome.org/content/detail/R-HSA-5693532 |
| KEGG | hsa:545 | https://www.genome.jp/dbget-bin/www_bget?hsa:545 |
| Human Protein Atlas | ENSG00000175054 | https://www.proteinatlas.org/ENSG00000175054-ATR |
| PharmGKB | PA134864160 | https://www.pharmgkb.org/gene/PA134864160 |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Shao, J., Huang, L., Lai, W., Zou, Y., & Zhu, Q. (2023). Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer. *Molecules*. https://www.semanticscholar.org/paper/a35c6e3f95e20f6d79df8c03526dc6b9273b0ce8

[2] Black, J., Crouch, K., Lemgruber, L., Lapsley, C., Dickens, N. J., Mottram, J., & McCulloch, R. (2018). The ATR kinase of Trypanosoma brucei links DNA damage signalling and monoallelic control of surface antigen gene expression during antigenic variation. *bioRxiv*. https://www.semanticscholar.org/paper/1690b631d5452664259fb0695b0cc472333c619d

[3] Chen, H., Pan, T., Zheng, X., Huang, Y., Wu, C., Yang, T., Gao, S., Wang, L., & Yan, S. (2023). The ATR-WEE1 kinase module promotes SUPPRESSOR OF GAMMA RESPONSE 1 translation to activate replication stress responses. *The Plant Cell*. https://www.semanticscholar.org/paper/2ac6d2906cde5ef8e5f3f5cd573a4c3a5bd131ea

[4] Forero, A., Giacobbi, N. S., McCormick, K., Gjoerup, O., Bakkenist, C., Pipas, J., & Sarkar, S. N. (2014). SV40 Large T antigen induces ISGs through ATR Kinase. *Journal of Immunology*. https://www.semanticscholar.org/paper/a78e36bb70835e22d18d76d51c2a30f8d9980646

[5] Tuul, M., Kitao, H., Iimori, M., Matsuoka, K., Kiyonari, S., Saeki, H., Oki, E., Morita, M., & Maehara, Y. (2013). Rad9, Rad17, TopBP1 and Claspin Play Essential Roles in Heat-Induced Activation of ATR Kinase and Heat Tolerance. *PLoS ONE*. https://www.semanticscholar.org/paper/42db2cc6860bd0917fa7b697bdaeb11ddaf790ab

[6] Muralikrishna, B., Chaturvedi, P., Sinha, K., & Parnaik, V. (2012). Lamin misexpression upregulates three distinct ubiquitin ligase systems that degrade ATR kinase in HeLa cells. *Molecular and Cellular Biochemistry*. https://www.semanticscholar.org/paper/001c1bb28ceb50e2eec2a77924a0c6cbc40659d8

[7] Pipas, J., Sarkar, S. N., Mccormick, Gjoerup, O., Bakkenist, C., Forero, A., & Giacobbi, N. S. (2014). IFN-Stimulated Genes through ATR Kinase Simian Virus 40 Large T Antigen Induces. *Scientific Publication*. https://www.semanticscholar.org/paper/8b0351cf841d77fe6befc1489872c39c7bdc2528

[8] Szurman-Zubrzycka, M., Nawrot, M., Jelonek, J., Dziekanowski, M., Kwasniewska, J., & Szarejko, I. (2019). ATR, a DNA Damage Signaling Kinase, Is Involved in Aluminum Response in Barley. *Frontiers in Plant Science*. https://www.semanticscholar.org/paper/e371c169d35e1abcd406d16aae5bf0389024400b

[9] Klein, A., Muijtjens, M., Os, R., Verhoeven, Y., Smit, B., Carr